Gilead Sciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GILD research report →
About the company
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs.
- CEO
- Daniel O'Day
- IPO
- 1992
- Employees
- 17,600
- HQ
- Foster City, CA, US
Price Chart
- Market Cap
- $162.98B
- P/E
- 17.69
- P/S
- 5.48
- P/B
- 6.93
- EV/EBITDA
- 12.67
- Div Yield
- 2.45%
- Gross Margin
- 79.35%
- Op Margin
- 38.26%
- Net Margin
- 30.99%
- ROE
- 42.16%
- ROIC
- 20.31%
- Revenue
- $29.44B · 2.39%
- Net Income
- $8.51B · 1672.92%
- EPS
- $6.84 · 1700.00%
- Op Income
- $11.70B
- FCF YoY
- -8.24%
- 52W High
- $157.29
- 52W Low
- $107.75
- 50D MA
- $129.60
- 200D MA
- $129.92
- Beta
- 0.34
- Avg Volume
- 7.18M
Get TickerSpark's AI analysis on GILD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | O'Day Daniel Patrick | sell | 11,900 |
| Jul 1, 26 | O'Day Daniel Patrick | sell | 3,100 |
| Jun 15, 26 | Mercier Johanna | sell | 1,480 |
| Jun 15, 26 | Mercier Johanna | sell | 1,070 |
| Jun 15, 26 | Mercier Johanna | sell | 450 |
| Jun 15, 26 | Dickinson Andrew D | sell | 3,000 |
| Jun 10, 26 | Berger Dietmar | other | 533 |
| Jun 10, 26 | Berger Dietmar | other | 533 |
| Jun 10, 26 | Berger Dietmar | other | 263 |
| Jun 10, 26 | Cain Wettan Keeley M | other | 589 |
Our GILD coverage
Recent articles, reports, and earnings notes.
Best biotech stocks for May 2026
These seven biotech stocks stand out for commercial strength, earnings quality, and pipeline depth, with Amgen leading this May 2026 ranking.
Merck’s latest data may have bought it more time than bears want to admit
Merck’s patent-cliff problem is real, but the market is acting like the runway ends tomorrow when the core franchise is still expanding today. Fresh lung-cancer data, rising Keytruda sales, and a packed oncology catalyst calendar make MRK look stronger than the fear trade suggests.
Want a deeper read on GILD?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.